No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Biotechnology
Quantum Genomics S.A., a biopharmaceutical firm established in Paris, France, in 2005, focuses on creating treatments for cardiovascular ailments. Its therapeutic approach utilizes the brain aminopeptidase A inhibition (BAPAI) platform, primarily addressing high blood pressure (hypertension) and heart failure. The company's key asset, firibastat, is currently undergoing a crucial Phase III study as a standalone therapy for hypertension and is also in clinical trials for heart failure. Additionally, Quantum Genomics is progressing QGC011 for hypertension in combination therapy, and further developing QGC006 and QGC606 to target both hypertension and heart failure.
www.quantum-genomics.comNo one on the platform currently holds ALQGC.PA.
No tracked institution reports a position in ALQGC.PA as of their last filing.
No one on the platform has traded ALQGC.PA yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| Rev. Growth % | -99.9% | -90.8% | ||||
| Profit Margin % | -88926030.0% | -17788896.0% | ||||
| Free Cash Flow Margin % | 0.0% | -405.1% | ||||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $159M | +694.4% | $5.96 | $5.96–$5.96 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 0 of the last 4 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2023-05-26 | $-0.18 | $-0.40 | -124.3% |
| 2022-05-02 | $-0.26 | $-0.41 | -58.8% |
| 2021-10-06 | $-0.19 | $-0.23 | -21.4% |
| 2021-03-25 | $0.08 | $-0.54 | -778.6% |
| $4M |
| — |
| ALMDP.PAMedesis Pharma S.A. | $0.35 | +0.00% | $2M | — |
| ALPHA.PAPharnext S.A. | $0.00 | +0.00% | $1190 | — |
Source: Financial Modeling Prep · peers by sector/industry